SEO	Predicted	Predicted end	Amino acid segment containing signal peptide
ID	beginning	nucleotide	(A=Alanine, C=Cysteine, D=Aspartic Acid, E=
NO:	nucleotide	location	Glutamic Acid, F=Phenylalanine, G=Glycine,
1.0.	location	corresponding	H=Histidine, I=Isoleucine, K=Lysine,
	corresponding	to first	L=Leucine, M=Methionine, N=Asparagine,
	to first	amino acid	P=Proline, Q=Glutamine, R=Arginine,
	amino acid	residue of	S=Serine, T=Threonine, V=Valine,
1	residue of	amino acid	W=Tryptophan, Y=Tyrosine, X=Unknown, *=Stop
	amino acid	sequence	Codon, /=possible nucleotide deletion,
	sequence	Sequence	\=possible nucleotide insertion)
	bequerice		ASNYNVPLSSTAQSTSARNSDSKLTWSPGSVTNTSLAHELWKVP
1			LPPKNITAPSRPPPGLTGQKPPLSTWDNSPLRIGGGWGNSDARY
			TPGSSWGESSSGRITNWLVLKNLTPQIDGSTLRTLCMQHGPLIT
7117	695	1261	FHLNLPHGNALVRYSSKEEVVKAQKSLHISDLFLLTL
1,11,	695	7597	LLISTPGGCHPPPSSIEFTYTGAWGKALPAPHMPCAPGALPQGA
			FVSQAARAIPLLQPSQAAQAEGLSQPARACGALCSLPWPLRNWG
1	1		SPILRLPGGLRTPTNDRKTRTRSAMACWARAQWDTLGPLKLSHR
1			GKVCLRHPRPTGVRGGPGAAGRQGGMGTRRRGTFTSGARDPGGL
			RVKHRCQPTGHLP
7118	49	1863	PHCEPNPGAGAMVLLHVLFEHAVGYALLALKEVEEISLLQPQVE
			ESVLNLGKFHSIVRLVAFCPFASSQVALENANAVSEGVVHEDLR
			LLLETHLPSKKKKVLLGVGDPKIGAAIQEELGYNCQTGGVIAEI
			LRGVRLHFHNLVKGLTDLSACKAQLGLGHSYSRAKVKFNVNRVD
ļ	J		NMIIQSISLLDQLDKDINTFSMRVREWYGYHFPELVKIINDNAT
			YCRLAQFIGNRRELNEDKLEKLEELTMDGAKAKAILDASRSSMG
			MDISAIDLINIESFSSRVVSLSEYRQSLHTYLRSKMSQVAPSLS
			ALIGEAVGARLIAHAGSLTNLAKYPASTVQILGAEKALFRALKT
ł	}		RGNTPKYGLIFHSTFIGRAAAKNKGRISRYLANKCSIASRIDCF
			SEVPTSVFGEKLREQVEERLSFYETGEIPRKNLDVMKEAMVQAE
1			EAAAEITRKLEKQEKKRLKKEKKRLAALALASSENSSSTPEECE
			EMSEKPKKKKKQKPQEVPQENGMEDPSISFSKPKKKKSFSKEEL
			MSSDLEETAGSTSIPKRKKSTPKEETVNDPEEAGHRSGSKKKRK
j			FSKEEPVSSGPEEAAGKSSSKKKKKFHKASQED
7119	49	1863	PHCEPNPGAGAMVLLHVLFEHAVGYALLALKEVEEISLLQPQVE
			ESVLNLGKFHSIVRLVAFCPFASSQVALENANAVSEGVVHEDLR
į			LLLETHLPSKKKKVLLGVGDPKIGAAIQEELGYNCQTGGVIAEI
			LRGVRLHFHNLVKGLTDLSACKAQLGLGHSYSRAKVKFNVNRVD
			NMIIQSISLLDQLDKDINTFSMRVREWYGYHFPELVKIINDNAT
ſ			YCRLAQFIGNRRELNEDKLEKLEELTMDGAKAKAILDASRSSMG
			MDISAIDLINIESFSSRVVSLSEYRQSLHTYLRSKMSQVAPSLS
			ALIGEAVGARLIAHAGSLTNLAKYPASTVQILGAEKALFRALKT
1			RGNTPKYGLIFHSTFIGRAAAKNKGRISRYLANKCSIASRIDCF
			SEVPTSVFGEKLREQVEERLSFYETGEIPRKNLDVMKEAMVQAE
ŀ			EAAAEITRKLEKQEKKRLKKEKKRLAALALASSENSSSTPEECE
			EMSEKPKKKKKQKPQEVPQENGMEDPSISFSKPKKKKSFSKEEL
l	Ì		MSSDLEETAGSTS I PKRKKSTPKEETVNDPEEAGHRSGSKKKRK
			FSKEEPVSSGPEEAAGKSSSKKKKKFHKASQED
7120	1991	64	QLGTRRCLRGDKVTNAMQDFLVTNLEPRFIEPQTANLSVVFKDS
			NSTTPLIFVLSPGTDPAADLYKFAEEMKFSKKLSAISLGQGQGP
			RAEAMMRSSIERGKWVFFQNCHLAPSWMPALERLIEHINPDKVH
			RDFRLWLTSLPSNKFPVSILQNGSKMTIEPPRGVRANLLKSYSS
			LGEDFLNSCHKVMEFKSLLLSLCLFHGNALERRKFGPLGFNIPY
			EFTDGDLRICISQLKMFLDEYDDIPYKVLKYTAGEINYGGRVTD
			DWDRRCIMNILEDFYNPDVLSPEHSYSASGIYHOIPPTYDLHGY
			LSYIKSLPLNDMPEIFGLHDNANITFAQNETFALLGTIIOLOPK
			SSSAGSQGREEIVEDVTQNILLKVPEPINLQWVMAKYPVLYEES
	[MNTVLVQEVIRYNRLLQVITQTLQDLLKALKGLVVMSSQLELMA
			ASLYNNTVPELWSAKAYPSLKPLSSWVMDLLQRLDFLQAWIQDG
			IPAVFWISGFFFPQAFLTGTLQNFARKFVISIDTISFDFKVMFE
			APSELTQRPQVGCYIHGLFLEGARWDPEAFQLAESQPKELYTEM
			AVIWLLPTPNRKAQDQDFYLCPIYKTLTRAGTLSTTGHSTNYVI
			AVIWLEPTPNRKAQDQDF1ECPTYRTETRAGTESTTGHSTNYVI AVEIPTHQPQRHWIKRGVALICALDY
7121	2	546	RPLRPWVLSLGSMVGLMTYGRRQFQSLDTTMRRLIPPFREASAK
,	-	240	1
			LTTLVDADAEAFTAYLEAMRLPKNTPEEKDRRTAALQEGLRRAV
			SVPLTLAETVASLWPALQELARCGNLACRSDLQVAAKALEMGVF
			GAYFNVLINLRDITDEAFKDQIHHRVSSLLQEAKTQAALVLDCL

SEQ	Predicted	Predicted end	Amino paid coment containing of mal	
ID	beginning	nucleotide	Amino acid segment containing signal peptide	
NO:	nucleotide	1	(A=Alanine, C=Cysteine, D=Aspartic Acid, E=	
NO:		location	Glutamic Acid, F=Phenylalanine, G=Glycine,	
	location	corresponding	H=Histidine, I=Isoleucine, K=Lysine,	
]	corresponding	to first	L=Leucine, M=Methionine, N=Asparagine,	
	to first	amino acid	P=Proline, Q=Glutamine, R=Arginine,	
	amino acid	residue of	S=Serine, T=Threonine, V=Valine,	
	residue of	amino acid	W=Tryptophan, Y=Tyrosine, X=Unknown, *=Stop	
1	amino acid	sequence	Codon, /=possible nucleotide deletion,	
	sequence		\=possible nucleotide insertion)	
			ETRQE	
7122	2	546	RPLRPWVLSLGSMVGLMTYGRRQFQSLDTTMRRLIPPFREASAK	
			LTTLVDADAEAFTAYLEAMRLPKNTPEEKDRRTAALQEGLRRAV	
	}		SVPLTLAETVASLWPALQELARCGNLACRSDLQVAAKALEMGVF	
1	}	ł	GAYFNVLINLRDITDEAFKDQIHHRVSSLLOEAKTOAALVLDCI,	
	i		ETROE	
7123	1	1092		
1123		1092	KPAVPEARSAGTSEAGRSGAEEVSCGSVSGDGAAMRLTPRALCS	
			AAQAAWRENFPLCGRDVARWFPGHMAKGLKKMQSSLKLVDCIIE	
1	ł.		VHDARIPLSGRNPLFQETLGLKPHLLVLNKMDLADLTEQQKIMQ	
	ŀ	·	HLEGEGLKNVIFTNCVKDENVKQIIPMVTELIGRSHRYHRKENL	
			EYCIMVIGVPNVGKSSLINSLRRQHLRKGKATRVGGEPGITRAV	
	})	MSKIQVSERPLMFLLDTPGVLAPRIESVETGLKLALCGTVLDHL	
			VGEETMADYLLYTLNKHQRFGYVQHYGLGSACDNVERVLKSVAV	
	1		KLGKTQKVKVLTGTGNVNVIQPNYPAAARDFLQTFRRGLLGSVM	
			LDLDVLRGHPRV	
7124	2	382	LPLTLLLAAPFAHLLLPPGHDQSPCWHPGPALSPGTLGPLSWAM	
ļ			ANSGLQLLGYFLALGGWVGIIASTALPQWKQSSYAGDASIQLRS	
			KVFVLESEWGGDSLGLPRDCGWSCLLHSAVRSEKGFWS	
7125	166	1127	NCISEKRNYSFSMQKGKGRTSRIRRRKLCGSSESRGVNESHKSE	
1.23	1	112/	FIELRKWLKARKFQDSNLAPACFPGTGRGLMSQTSLQEGQMIIS	
			I DECCLIE A DEMILIERAT CANTERWAY DECELE TO CHER MODERN	
1			LPESCLLT\RDTVIRSYLGAYITKWKPPPSPLLALCTFLVSEKH	
			AGHRSLLEA\YLEILPKAYTCPVCLEPEVVNLLPKSLKAKAEEQ	
'			RAHVQEFFASSRDFFSSLQPLFAEAVDSIFSYSALLWAWCTVNT	
1	J		RAVYL\SPGSGNAFLQSRTPVQLAPYLDLLNHSPHVQVKAAFNE	
			ETHSYEIRTTSRWRKHEEVFICYGPHDNQRLFLEYGFVSVHNPH	
			ACVYVSRGWNQLCS	
7126	1	733	CRDMAAFIVPSPARRCSQKGSLGHLPTQPWLWAAMSPRGQERGT	
	[SHSQAREPQRPGRWLLGSLQSSPGTLGQAGTASRRRGCMVQRWV	
			QVATGRRAVQVPKGALGLALGETSPGASRGMSGGAGGCWALGWA	
			PSPVLPSWLLEGPPPWLSIISDSGTQRPSPRRCPARPSPWGPQC	
ł			WRGGRIASAEASST*TPGSGSRARSGRRSPGSRRRSASAPSPTP	
			PTDACA*SCVARPAGSRSSRPAAA	
7127	1311	277	GLPAMCST*KAGYYEETEGDCIPKDR*IEKRPFKEI*RRIPRIF	
i			AKQKQI*S*NSQKIGASEIDRGRKEADCSDAPAAARIGAVSVFR	
ł			RSTQEARVSPRSNAKSANLRAVRAD*WEHFVLLFHTPEQFLAEC	
1		•	ICRST**K*WHQLC*PLSSL*TGLKRKLLL*VLFRI*WLKDCDV	
			*FCQKIFATNFCNWQNLIQ*EE*KPVEYSVEN*HIMNLLLPM*	
]		CQSSLRDQTIVTWRM*RNYSMFRINMISSL*DGSIHIPLKLHFY	
	[PALIFTLTVPINSCCQRPLPLFAHQSIKTLASSGSPMLACLRFL	
7100			LVKKRAFIHTPRSPGCSV*CKHVLVKDNKNNCVGSEV	
7128	2	5228	GRVDLWTILLGRSALRELSQIEAELNKHWRRLLEGLSYYKPPSP	
			SSAEKVKANKDVASPLKELGLRISKFLGLDEEQSVQLLQCYLQE	
			DYRGTRDSVKTVLQDERQSQALILKIADYYYEERTCILRCVLHL	
			LTYFQDERHPYRVEYADCVDKLEKELVSKYRQQFEELYKTEAPT	
[WETHGNLMTERQVSRWFVQCLREQSMLLEIIFLYYAYFEMAPSD	
]			LLVLTKMFKEQGFGSRQTNRHLVDETMDPFVDRIGYFSALILVE	
1			GMDIESLHKCALDDRRELHQFAQDGLICQDMDCLMLTFGDIPHH	
1 1			APVLLAWALLRHTLNPEETSSVVRKIGGTAIQLNVFQYLTRLLQ	
}			SLASGGNDCTTSTACMCVYGLLSFVLTSLELHTLGNQQDIIDTA	
}			CEVLADPSLPELFWGTEPTSGLGIILDSVCGMFPHLLSPLLQLL	
; !			RALVSGKSTAKKVYSFLDKMSFYNELYKHKPHDVISHEDGTLWR	
			RQTPKLLYPLGGQTNLRIPQGTVGQVMLDDRAYLVRWEYSYSSW	
			TLFTCEIEMLLHVVSTADVIQHCQRVKPIIDLVHKVISTDLSIA	
j l				
j [DCLLPITSRIYMLLQRLTTVISPPVDVIASCVNCLTVLAARNPA	
			KVWTDLRHTGFLPFVAHPVSSLSQMISAEGMNAGGYGNLLMNSE	
Ll			QPQGEYGVTIAFLRLITTLVKGQLGSTQSQGLVPCVMFVLKEML	

- 252				
SEQ ID	Predicted	Predicted end	Amino acid segment containing signal peptide	
NO:	beginning nucleotide	nucleotide	(A=Alanine, C=Cysteine, D=Aspartic Acid, E=	
) NO:	location	location	Glutamic Acid, F=Phenylalanine, G=Glycine,	
1	corresponding	corresponding to first	H=Histidine, I=Isoleucine, K=Lysine,	
}	to first	amino acid	L=Leucine, M=Methionine, N=Asparagine,	
	amino acid	residue of	P=Proline, Q=Glutamine, R=Arginine,	
1	residue of	amino acid	S=Serine, T=Threonine, V=Valine,	
	amino acid	1	W=Tryptophan, Y=Tyrosine, X=Unknown, *=Stop	
	sequence	sequence	Codon, /=possible nucleotide deletion,	
	sequence		\=possible nucleotide insertion)	
i			PSYHKWRYNSHGVREQIGCLILELIHAILNLCHETDLHSSHTPS	
ì			LQFLCICSLAYTEAGQTVINIMGIGVDTIDMVMAAQPRSDGAEG	
			QGQGQLLIKTVKLAFSVTNNVIRLKPPSNVVSPLEQALSQHGAH	
1	ĺ		GNNLIAVLAKYIYHKHDPALPRLAIQLLKRLATVAPMSVYACLG	
			NDAAAIRDAFLTRLQSK\IE\DMRIK\VMIL\EFLTVA\VETQP	
			GLIELFLNLEVKDG\SDGSKEFSLGMW\SCLHAV/VWELIDSQQ	
1			QDRYWCPPLLHRAAIAFLHALWQDRRDSAMLVLRTKPKFWENLT	
			SPLFGTLSPPSETSEPSILETCALIMKIICLEIYYVVKGSLDQP	
1	}		LKDTLKKFSIEKRFAYWSGYVKSLAVHVAETEGSSCTSLLEYQM	
			LVSAWRMLLIIATTHADIMHLTDSVVRRQLFLDVLDGTKALLLV	
			PASVNCLRLGSMKCTLLLILLRQWKRELGSVDEILGPLTEILEG	
1			VLQADQQLMEKTKAKVFSAFITVLQMKEMKVSDIPQYSQLVLNV	
			CETLQEEVIALFDQTRHSLALGSATEDKDSMETDDCSRSRHRDQ	
1			RDGVCVLGLHLAKELCEVDEDGDSWLQVTRRLPILPTLLTTLEV	
			SLRMKQNLHFTEATLHLLLTLARTQQGATAVAGAGITQSICLPL	
			LSVYQLSTNGTAQTPSASRKSLDAPSWPGVYRLSMSLMEQLLKT	
			LRYNFLPEALDFVGVHQERTLQCLNAVRTVQSLACLEEADHTVG	
1			FILQLSNFMKEWHFHLPQLMRDIQVNLGYLCQACTSFLHSRKML	
			QHYLQNKNGDGLPSAV\AQRV\QRPPSAASAAPSSSKQPAADTE	
			ASEQQALHTVQYGLLKILSKTLAALRHFTPDVCQILLDQSLDLA	
			EYNFLFALSFTTPTFDSEVAPSFGTLLATVNVALNMLGELDKKK	
			EPLTQAVGLSTQAEGTRTLKSLLMFTMENCFYLLISQAMRYLRD	
			PAVHPRDKQRMKQELSSELSTLLSSLSRYFRRGAPSSPATGVLP	
7129	1	1054	SPQGKSTSLSKASPESQEPLIQLVQAFVRHMQR	
1125	_	1034	FRRFRWRRLH*AGPASSAGGSPGEASGTMSGELPPNINIKEPR	
			WDQSTFIGRANHFFTVTDPRNILLTNEQLESARKIVHDYRQGIV	
			PPGLTENELWRAKYIYDSAFHPDTGEKMILIGRMSAQVPMNMTI	
			TGCMMTFYRTTPAVLFWQWINQSFNAVVNYTNRSGDAPLTVNEL	
			GTAYVSATTGAVATALGLNALTKHVSPLIGRFVPFAAVAAANCI	
			NIPLMRQRELKVGIPVTDENGNRLGESANAAKQAITQVVVSRIL	
			MAAPGMAIPPFIMNTLEKKAFLKRFPWMSAPIQVGLVGFCLVFA	
7130	2	780	TPLCCALFPQKSSMSVTSLEAELQAKIQESHPELRRVYFNKGL	
7130	4	/80	HEVPSLQTSDPLPGSVQRCSVVVSQPNKENWCQDHLYNSLGRKG	
			ISAKSQPYHRSQSSSSVLINKSMDSINYPSDVGKQQLLSLHRSS	
			RCESHQDLLPDIADSHQQGTEKLSDLTLQDSQKVVVVNRNLPLN	
			AQIATQNYFSNFKETDGDEDDYVEIKSEEDESELELSHNRRRKS	
			DSKFVDADFSDNVCSGNTLHSLNSPRTPKKPVNSKLGLSPYLTP	
7131	805	<u> </u>	YNDSDKLNDYLWRGPSPNQQNIVQSLREKFQCLSSSSFA	
,,,,,	005	573	AAAEGHIEVVKFLIEACKVNPFAKDRWGNIPLDDAVQFNHLEVV	
7132	1420	1007	KILLQDYQDSYTLSETQAEAAAEALSKENLESMV	
1,134	1420	1087	IDMLLLSGALVSGPYTLITTAVSADLGTHKSLKGNAHALSTVTA	
			IIDGTGSVGAALGPLLAGLLSPSGWSNVFYMLMFADACALLFLI	
7133		3548	RLIHKELSCPGSATGDQVPFKEQ	
1133	2	3648	QQIPGLLPAHGESGDALRKPRLQKPITGHLDDLFFTLYPSLEKF	
			EEELLELHVQDHFQEGCGPLDGGALEILERRLRVGVHNGLGFVQ	
			RPQVVVLVPEMDVALTRSASFSRKVVSSSKTSSGSQALVLRSRL	
			RLPEMVGHPAFAVIFQLEYVFSSPAGVDGNAASVTSLSNLACMH	
•			MVRWAVWNPLLEADSGRVTLPLQGGIQPNPSHCLVYKVPSASMS	
	!		SEEVKQVESGTLRFQFSLGSEEHLDAPTEPVSGPKVERRPSRKP	
			PTSPSSPPAPVPRVLAAPQNSPVGPGLSISQLAASPRSPTQHCL	
{			ARPTSQLPHGSQASPAQAQEFPLEAGISHLEADLSQTSLVLETS	
			IAEQLQELPFTPLHAPIVVGTQTRSSAGQPSRASMVLLQSSGFP	
			EILDANKQPAEAVSATEPVTFNPQKEESDCLQSNEMVLQFLAFS	
			RVAQDCRGTSWPKTVYFTFQFYRFPPATTPRLQLVQLDEAGQPS	
			SGALTHILVPVSRDGTFDAGSPGFQLRYMVGPGFLKPGERRCFA	
			RYLAVQTLQIDVWDGDSLLLIGSAAVQMKHLLRQGRPAVQASHE	

SEQ	Predicted	Predicted end		
ID	beginning	nucleotide	Amino acid segment containing signal peptide (A=Alanine, C=Cysteine, D=Aspartic Acid, E=	
NO:	nucleotide	location	Glutamic Acid, F=Phenylalanine, G=Glycine,	
1	location	corresponding	H=Histidine, I=Isoleucine, K=Lysine,	
	corresponding	to first	L=Leucine, M=Methionine, N=Asparagine,	
	to first	amino acid	P=Proline, Q=Glutamine, R=Arginine,	
	amino acid	residue of	S=Serine, T=Threonine, V=Valine,	
	residue of	amino acid	W=Tryptophan, Y=Tyrosine, X=Unknown, *=Stop	
1	amino acid	sequence	Codon, /=possible nucleotide deletion,	
	sequence		\=possible nucleotide insertion)	
			LEVVATEYEQDNMVVSGDMLGFGRVKPIGVHSVVKGRLHLTLAN	
			VGHPCEQKVRGCSTLPPSRSRVISNDGASRFSGGSLLTTGSSRR	
1	ĺ	İ	KHVVQAQKLADVDSELAAMLLTHARQGKGPQDVSRESDATRRK	
ŀ			LERMRSVRLQEAGGDLGRRGTSVLAQQSVRTQHLRDLQVIAAYR ERTKAESIASLLSLAITTEHTLHATLGVAEFF3FVLKNPHNTQH	
			TVTVEIDNPELSVIVDSQEWRDFKGAAGLHTPVEEDMFHLRGSL	
			APQLYLRPHETAHVPFKFQSFSAGQLAMVQASPGLSNEKGMDAV	
1	ĺ		SPWKSSAVPTKHAKVLFRASGGKPIAVLCLTVELQPHVVDQVFR	
	ļ]	FYHPELSFLKKAIRLPPWHTFPGAPVGMLGEDPPVHVRCSDPNV	
			ICETQNVGPGEPRDIFLKVASGPSPEIKDFFVIIYSDRWLATPT	
1			QTWQVYLHSLQRVDVSCVAGQLTRLSLVLRGTQTVRKVRAFTSH	
			PQELKTDPKGVFVLPPRGVQDLHVGVRPLRAGSRFVHLNLVDVD	
			CHQLVASWLVCLCCRQPLISKAFEIMLAAGEGKGVNKRITYTNP	
			YPSRRTFHLHSDHPELLRFREDSFQVGGGETYTIGLQFAPSQRV	
7134	2115	1111	GEEEILIYINDHEDKNEEAFCVKVIYQ	
1,131	2113	1111	GGEGFSYPPHVGLSLGTPLDPHYVLLEVHYDNPTYEEGLIDNSG LRLFYTMDIRKYDAGVIEAGLWVSLFHTIPPGMPEFQSEGHCTL	
			ECLEEALEAEKPSGIHVFAVLLHAHLAGRGIRLRHFRKGKEMKL	
			LAYDDDFDFNFQEFQYLKEEQTILPGDNLITECRYNTKDRAEMT	
		ĺ	WGGLSTRSEMCLSYLLYYPRINLTRCASIPDIMEQLQFIGVKEI	
			YRPVTTWPFIIKSPKQYKNLSFMDAMNKFKWTKKEGLSFNKLVL	
,			SLPVNVRCSKTDNAEWSIQGMTALPPDIERPYKAEPLVCGTSSS	
			SSLHRDFSINLLVCLLLLSCTLSTKSL	
7135	2	2072	FVPRVTPRSLSLQGPKGESVGSITQPLPSSYLIFRAASESDGRC	
			WLDALELALRCSSLLRLGTCKPGRDGEPGTSPDASPSSLCGLPA	
			SATVHPDQDLFPLNGSSLENDAFSDKSERENPEESDTETQDHSR	
1		J	KTESGSDQSETPGAPVRRGTTYVEQVQEELGELGELGEASQVETVSE	
			ENKSLMWTLLKQLRPGMDLSRVVLPTFVLEPRSFLNKLSDYYYH ADLLSRAAVEEDAYSRMKLVLRWYLSGFYKKPKGIKKPYNPILG	
			ETFRCCWFHPQTDSRTFYIAEQVSHHPPVSAFHVSNRKDGFCIS	
			GSITAKSRFYGNSLSALLDGKATLTFLNRAEDYTLTMFYAHCKG	
f			ILYGTMTLELGGKVTIECAKNNFQAQLEFKLKPFFGGSTSINQI	
			SGKITSGEEVLASLSGHWDRDVFIKEEGSGSSALFWTPSGEVRR	
			QRLRQHTVPLEEQTELESERLWQHVTRAISKGDQHRATQEKFAL	
			EEAQRQRARERQESLMPWKPQLFHLDPITQEWHYRYEDHSPWDP	
	[i	LKDIAQFEQDGILRTLQQEAVARQTTFLGSPGPRHERSGPDQRL	
		ł	RKASDQPSGHSQATESSGSTPESCPELSDEEQDGDFVPGGESPC	
			PRCRKEARRLQALHEAILSIREAQQELHRHLSAMLSSTARAAQA PTFGLLQSPRSWFLLCVFLACOLFINHILK	
7136	2	418	DFVPSFRRPSGNTSQTVWLLRAATLEKEVAGLREKIHHLDDMLK	
	-	122	SQQRKVRQMIEQLQNSKAVIQSKDATIQELKEKIAYLEAENLEM	
		ı	HDRMEHLIEKQISHGNFSTQARAKTENPGSIRISKPPSPKPMPV	
J I			IRVVET	
7137	2	466	WASGMSTVPGGSRHSLGIQVRGGWGVTGGEEESLTVPVADTWQA	
			GSFKVATQERNPQRAQMRLRRQKKGVVPFLGDFLTELQRLDSAI	
			PDDLDGNTNKRSKEVRVLQEMQLLQVAAMNYRLRPLEKFVTYFT	
			RMEQLSDKESYKLSCQLEPENP	
7138	2	466	WASGMSTVPGGSRHSLGIQVRGGWGVTGGEEESLTVPVADTWQA	
			GSFKVATQERNPQRAQMRLRRQKKGVVPFLGDFLTELQRLDSAI	
			PDDLDGNTNKRSKEVRVLQEMQLLQVAAMNYRLRPLEKFVTYFT	
7139	7		RMEQLSDKESYKLSCQLEPENP	
'139	1	357	SLRNSARGLKMAASAARGAAALRRSINQPVAFVRRIPWTAASSQ	
			LKEHFAQFGHVRRCILPFDKETGFHRGLGWVQFSSEEGLRNALQ QENHIIDGVKVQVHTRRPKLPQTSDDEKKDF	
7140	1401	1957	RASSLQVLKAWGGLIPSSFQQQHTGQYALEELFDLKVYDCFCSF	
	~	- · · · · · · · · · · · · · · · · · · ·	(1446669	
/==0			NMNVSLEKQLRPSQPWPRGKCRKTPGWEEARPKAQDLRGDLGKT	

SEO	Predicted	Predicted end	Amino agid gagment gentaining sing 3	
ID	beginning	nucleotide	Amino acid segment containing signal peptide	
NO:	nucleotide	location	(A=Alanine, C=Cysteine, D=Aspartic Acid, E=	
1,0.	location	corresponding	Glutamic Acid, F=Phenylalanine, G=Glycine,	
ļ	corresponding	to first	H=Histidine, I=Isoleucine, K=Lysine,	
	to first	amino acid	L=Leucine, M=Methionine, N=Asparagine,	
	amino acid	residue of	P=Proline, Q=Glutamine, R=Arginine,	
	residue of	amino acid	S=Serine, T=Threonine, V=Valine,	
Ĭ	amino acid		W=Tryptophan, Y=Tyrosine, X=Unknown, *=Stop	
	sequence	sequence	Codon, /=possible nucleotide deletion,	
<u> </u>	sequence		\=possible nucleotide insertion)	
1			QAGPAEAHTRGPPRLPAATGCPPHLPGLLSGISVDIDPTGLQSQ	
ł	1	1	WTPKGQDPPLMFSEDYQKSLLEQYHLGLDQKLRKYVVGELIWNF	
			ADFMTNQCG	
7141	124	1073	LDSRSCWLDMEDLEEDVRFIVDETLDFGGLSPSDSREEEDITVL	
1			VTPEKPLRRGLSHRSDPNAVAPAPQGVRLSLGPLSPEKLEEILD	
ŀ	J	J	EANRLAAQLEQCALQDRESAGEGLGPRRVKPSPRRETFVLKDSP	
			VRDLLPTVNSLTRSTPS/LKQPDASTPE***EGVSQGSPGYIWK	
			EALQHEEGVTHLQSVPCIQKPSIFSS\SRSTPPVRGRAGPSGRA	
1			AASEETRAAKLRGAAAKSSCQLPIPSAIPRPASRMPLTSRSVPP	
			GRGALPPDSLSTRKGLPRPSTAGHRVRESGHKVPVSQRLNLPVM	
			GATRSNLQPP	
7142	658	839	LIFLMLHMELKMLSSVTLHIRAFLYWICLKPTSCLIFQNVLNLL	
			KK*SRAVGVVVVMCRT/YSSDLQVGVIKPWLLLGSQDAAHDLDT	
			LKKNKVTHILNVAYGVENAFLSDFTYKSISILDLPETNILSYFP	
			ECFEFIEEAKRKDGVVLVHCNA	
7143	3	773	SLEMSSDGEPLSRMDSEDSISSTIMDVDSTISSGRSTPAMMNGQ	
	[GSTTSSSKNIAYNCCWDQCQACFNSSPDLADHIRSIHVDGQRGG	
	ļ		VFVCLWKGCKVYNTPSTSQSWLQRHMLTHSGDKPFKCVVGGCNA	
1			SFASQGGLARHVPTHFSQQNSSKVSSQPKAKEESPSKAGMNKRR	
			KLKNKRRRSLARPHDFFDAQTLDAIRHRAICFNLSAHIESLGKG	
			HSVVFHSTVSILLFFQIKYKTLQKNISTIISKSLKI	
7144	1	988	FRVNMQDGGPSPAEHSKAEESAGMEARFLGLPDAAGSSGPTPAR	
			RCPAPRPAGVSYVIRDEVEKYNRNGVNALQLDPALNRLFTAGRD	
			SIIRIWSVNQHKQDPYIASMEHHTDWVNDIVLCCNGKTLISASS	
			DTTVKVWNAHKGFCMSTLRTHKDYVKALAYAKDKELVASAGLDR	
			QIFLWDVNTLTALTASNNTVTTSSLSGNKDSIYSLAMNQLGTII	
			VSGSTEKVLRVWDPRTCAKLMKLKGHTDNVKALLLNRDGTQCLS	
			GSSDGTIRLWSLGQQRCIATYRVHDEGVWALQVNDAFTHVYSGG	
			RDRKIYCTDLRNPDIRVLICE	

TRADOCS:1416260.1(%CSK01!.DOC)

WHAT IS CLAIMED IS:

- 1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1-1786 and 3573-5358, a mature protein coding portion of SEQ ID NO:1-1786 and 3573-5358, an active domain of SEQ ID NO:1-1786 and 3573-5358, and complementary sequences thereof.
- 2. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide hybridizes to the polynucleotide of claim 1 under stringent hybridization conditions.
- 3. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide has greater than about 90% sequence identity with the polynucleotide of claim 1.
- 4. The polynucleotide of claim 1 wherein said polynucleotide is DNA.
- 5. An isolated polynucleotide of claim 1 wherein said polynucleotide comprises the complementary sequences.
- 6. A vector comprising the polynucleotide of claim 1.
- 7. An expression vector comprising the polynucleotide of claim 1.
- 8. A host cell genetically engineered to comprise the polynucleotide of claim 1.
- 9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.
- 10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of:

PCT/US00/34263

http://www.patentions.net/

WO 01/53312

(a) a polypeptide encoded by any one of the polynucleotides of claim 1; and

- (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO:1-1786 and 3573-5358.
- 11. A composition comprising the polypeptide of claim 10 and a carrier.
- 12. An antibody directed against the polypeptide of claim 10.
- 13. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
- a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and
- b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.
- 14. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
- a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;
- b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and
- c) detecting said product and thereby the polynucleotide of claim 1 in the sample.
- 15. The method of claim 14, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.
- 16. A method for detecting the polypeptide of claim 10 in a sample, comprising:

http://www.patentions.net/

a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and

- b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.
- 17. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
- a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and
- b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.
- 18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
- a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and
- b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.
- 19. A method of producing the polypeptide of claim 10, comprising,
- a) culturing a host cell comprising a polynucleotide sequence selected from the group consisting of a polynucleotide sequence of SEQ ID NO:1-1786 and 3573-5358, a mature protein coding portion of SEQ ID NO:1-1786 and 3573-5358, an active domain of SEQ ID NO:1-1786 and 3573-5358, complementary sequences thereof and a polynucleotide sequence hybridizing under stringent conditions to SEQ ID NO:1-1786 and 3573-5358, under conditions sufficient to express the polypeptide in said cell; and
 - b) isolating the polypeptide from the cell culture or cells of step (a).

PCT/US00/34263

WO 01/53312

http://www.patentions.net/

20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of any one of the polypeptides SEQ ID NO:1787 -3572 and 5359-7144, the mature protein portion thereof, or the active domain thereof.

- 21. The polypeptide of claim 20 wherein the polypeptide is provided on a polypeptide array.
- 22. A collection of polynucleotides, wherein the collection comprising the sequence information of at least one of SEQ ID NO:1-1786 and 3573-5358.
- 23. The collection of claim 22, wherein the collection is provided on a nucleic acid array.
- The collection of claim 23, wherein the array detects full-matches to any one of 24. the polynucleotides in the collection.
- 25. The collection of claim 23, wherein the array detects mismatches to any one of the polynucleotides in the collection.
- 26. The collection of claim 22, wherein the collection is provided in a computerreadable format.
- 27. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.
- 28. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising an antibody that specifically binds to a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.

http://www.patentions.net/

Image is corrupt.

INTERNATIONAL SEARCH REPORT

International application No.

	in the state of th	PC17US00/3	7263	
	SSIFICATION OF SUBJECT MATTER			
IPC(7) : C07H 21/04; C12N 15/11, 15/63, 15/70, 15/82, 15/85; C07K 14/00				
	US CL: 536/23.1; 435/320.1, 455, 468, 530/300, 350 According to International Patent Classification (IPC) or to both national classification and IPC			
	DS SEARCHED	tional classification and IFC		
	cumentation searched (classification system followed 36/23.1; 435/320.1, 455, 468, 530/300, 350	by classification symbols)		
Documentation	on searched other than minimum documentation to the	extent that such documents are include	ded in the fields searched	
Electronic da MEDLINE,	ata base consulted during the international search (name	e of data base and, where practicable	search terms used)	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.	
A	WAJIMA et al. The cDNA cloning and transient ex hydroxysteroid dehydrogenase of chickens. Gene. It		1-11, 13-16, and 19-26	
A	US 5,175,095 A (MARTINEAU et al) 29 Decembe columns 3-18.	r 1992 (29.12.1992), see especially	1-11, 13-16, and 19-26	
A	Database PubMed, ID No. 2393392, FREUDENSTEIN et al. mRNA of bovine tissue inhibitor of metalloproteinase: sequence and expression in bovine ovarian tissue. Biochem. Biophys. Res. Commun. August 1990. Vol.171. No. 1. pages 250-256, see Abstract.		1-11, 13-16, and 19-26	
A,P Database PubMed, ID No. 10919256, HENNEBOI generation and characterization of an ovary-selective library. Endocrinology. August 2000. Vol.141. No.		complementary deoxyribonucleic aci	d 1-11, 13-16, and 19-26	
A	Database PubMed, ID No. 2760883, BEIL et al. Sy the baboon (Papio anubis). J. Reprod. Fertil. July 19 Abstract.			
A,P Database PubMed, ID No. 10830289, HINSHELW upstream of the human CYP19 (aromatase) gene me transgenic mice. Endocrinology, June 2000. Vol.14		ediates ovary-specific expression in		
	·			
Further	documents are listed in the continuation of Box C.	See patent family annex.		
* S	pecial categories of cited documents:		e international filing date or priority	
"A" document defining the general state of the art which is not considered to be of particular relevance		principle or theory underlying th		
E" earlier application or patent published on or after the international filing date		considered novel or cannot be co	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination		
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious ') a person skilled		
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent family		
Date of the ac	ctual completion of the international search	Date of mailing of the international	search report	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT		Authorized officer Ash Marsh Michael Woodward	Ur Illen for	
Washington, D.C. 20231 Facsimile No. (703)305-3230		Telephone No. (703) 308-0196	- //	

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/34263

	PC 170300/34263		
Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)			
This international report has not been established in respect of certain claims under Article	17(2)(a) for the following reasons:		
1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority	ority, namely:		
Claim Nos.: because they relate to parts of the international application that do not comply an extent that no meaningful international search can be carried out, specification.			
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the	second and third sentences of Rule 6.4(a).		
Box II Observations where unity of invention is lacking (Continuation of Item	n 2 of first sheet)		
This International Searching Authority found multiple inventions in this international applica This includes 4 invention Groups and 3572 sequence species	ation, as follows:		
 As all required additional search fees were timely paid by the applicant, this is searchable claims. As all searchable claims could be searched without effort justifying an addition payment of any additional fee. As only some of the required additional search fees were timely paid by the accovers only those claims for which fees were paid, specifically claims Nos.: 	onal fee, this Authority did not invite		
4. No required additional search fees were timely paid by the applicant. Conseq restricted to the invention first mentioned in the claims; it is covered by claim Remark on Protest The additional search fees were accompanied by the application of No protest accompanied the payment of additional search fees.	as Nos.: ant's protest.		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/34263

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional serch fees must be paid. Group I, claims 1-11, 13-16, and 19-26, drawn to nucleic acid molecules, vector molecules and host cells containing said nucleic acids, polypeptides, methods of making said polypeptides and method of detection using said nucleic acids and polypeptides. Group II, claim 12 and 28, drawn to antibodies and method of treatment using composition comprising said antibodies. Group III, claims 17-18, drawn to methods of indentifying a binding partner to a polypeptides. Group IV, claim 27, drawn to method of treatment using composition comprising polypeptides.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, udner PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I encompasses nucleic acids, polypeptides expressed thereby, vectors and host cells containg same, respectively, and methods of making as well as the first method of use of this jubject matter. Groups II-V all are directed to different special technical features as summarized as follows: Group II is directed to an antibody and method of treatment using same, which antibody undergoes recognition and binding reactions wherein what is bound is different from what is bound by the compositions of Group I. For example, the polypeptides of Group I do not bind the polypeptides of Group I as the antibody of Group II does. Identification of binding partner and treatment are clearly different special technical features from detection. Group III is directed to the identification of a binding partner of a polypeptide, which is not identified in any of the other Groups and thus clearly contains its own special technical feature. Group IV is directed to treatment, which is a clearly different methods than the methods in the other Groups. Thus, in summary, each of Groups I-IV are directed to different special technical features and thus support this lack of unity.

Additionally, each of the claims is directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows: The claims include a series of polynucleotides and the polypeptides encoded thereby as represented by the sequences of SEQ ID Nos: 1-1786, and 3573-5358. Each of these polynucleotide sequences encodes a separate polypeptide and thus represent a separate gene. Therefore, each of these genes defines its own special technical feature. In summary, one species is a gene represented by one polynucleotide sequence and one polypeptide sequence encoded thereby.